Re: Farmas USA
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Posters Detailing ACH-1625, ACH-3102 and ACH-2928 Presented at the International Liver Congress(TM) 2012
NEW HAVEN, Conn., April 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that in the second segment of its Phase 2a trial of ACH-1625, 94 to 100 percent of patients with treatment naïve genotype 1 chronic hepatitis C virus (HCV) achieved a complete early virologic response (cEVR) after 12 weeks of treatment with ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R). ACH-1625 in combination with P/R for up to 12 weeks was safe and well tolerated and produced high viral response rates regardless of dose level or IL28B genotype status.
Click here for release.
You are subscribed to Achillion Pharmaceuticals Investor Relations''
To update your e-mail and alert preferences, please click here.
To unsubscribe, please click here.
Achillion Pharmaceuticals
300 George St. , New Haven, CT 06511
Service provided by Shareholder.com
DE HOY.........Framus +161179.
Luego en privi os contesto los prv de ayer.
Aunque la noticia DE HOY ya dice todo.....
EDITO creo que nos iremos de vacas gratis......